Bharat Biotech is intending to launch their vaccine covaxin for COVID-19 in the second quarter of 2021, after the confirmation from Indian regulatory authorities. They are focusing to conduct their Phase 3 trails across the country.
Covaxin– has been developed by a team of Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV) utilizing inactivated Sars-Cov-2, the infection that causes COVID-19. The infection has been isolated in an ICMR lab.
“If we get all the approvals after establishing strong experimental evidence and data, and efficacy and safety data in our last stage of trials, we aim to launch the vaccine in Q2 of 2021,” – Bharat Biotech International Executive Director Sai Prasad told.
The preliminary trials to be conducted in 25 to 30 cities across 13-14 states will give two portions each to the vaccine and placebo recipients. Around 2,000 subjects could be enlisted per hospital.
They going to invest around 350 -400 crore for the development of vaccine and new manufacturing outlets and looking to supply for both government and private markets.
After the organization got an endorsement from the Drugs Controller General of India (DCGI) to conduct Phase 3 clinical trials to build up the adequacy of the vaccine candidate, it has started trial activities for Phase 3, recruitment and dosage will start in November.
Price of the vaccine is yet to decide and the company is looking for cost of product development. Immediately they going to conduct phase 3 trails successfully across all the sites.
Latest corona records in INDIA:
India Corona Cases: 8,185,881